SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Isenberg D. A.)
 

Sökning: WFRF:(Isenberg D. A.) > Remission and low d...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006508naa a2200781 4500
001oai:lup.lub.lu.se:d903e1cb-1655-4f7b-a6c8-91fd6c2ad656
003SwePub
008240613s2024 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/d903e1cb-1655-4f7b-a6c8-91fd6c2ad6562 URI
0247 a https://doi.org/10.1136/ard-2024-2256132 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Barber, Megan R.W.u Cumming School of Medicine4 aut
2451 0a Remission and low disease activity are associated with lower healthcare costs : results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
264 1c 2024
520 a Objectives: This study aims to determine the independent impact of definitions of remission/low disease activity (LDA) on direct/indirect costs (DCs, ICs) in a multicentre inception cohort. Methods: Patients from 31 centres in 10 countries were enrolled within 15 months of diagnosis and assessed annually. Five mutually exclusive disease activity states (DAS) were defined as (1) remission off-treatment: clinical (c) SLEDAI-2K=0, without prednisone/immunosuppressants; (2) remission on-treatment: cSLEDAI-2K=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; (3) LDA-Toronto Cohort (TC): cSLEDAI-2K≤2, without prednisone/immunosuppressants; (4) modified lupus LDA state (mLLDAS): SLEDAI-2K≤4, no activity in major organs/systems, no new activity, prednisone ≤7.5 mg/day and/or maintenance immunosuppressants and (5) active: all remaining assessments. At each assessment, patients were stratified into the most stringent DAS fulfilled and the proportion of time in a DAS since cohort entry was determined. Annual DCs/ICs (2021 Canadian dollars) were based on healthcare use and lost workforce/non-workforce productivity over the preceding year. The association between the proportion of time in a DAS and annual DC/IC was examined through multivariable random-effects linear regressions. Results: 1692 patients were followed a mean of 9.7 years; 49.0% of assessments were active. Remission/LDA (per 25% increase in time in a remission/LDA state vs active) were associated with lower annual DC/IC: remission off-treatment (DC -$C1372; IC -$C2507), remission on-treatment (DC -$C973; IC -$C2604,) LDA-TC (DC -$C1158) and mLLDAS (DC -$C1040). There were no cost differences between remission/LDA states. Conclusions: Our data suggest that systemic lupus erythematosus patients who achieve remission, both off and on-therapy, and reductions in disease activity incur lower costs than those experiencing persistent disease activity.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a Economics
653 a Epidemiology
653 a Health services research
653 a Lupus Erythematosus, Systemic
653 a Risk Factors
7001 a Ugarte-Gil, Manuel Franciscou Hospital Nacional Guillermo Almenara Irigoyen, EsSalud,Scientific University of the South, Lima4 aut
7001 a Hanly, John G.u Dalhousie University4 aut
7001 a Urowitz, Murray B.u Toronto Western Hospital4 aut
7001 a St-Pierre, Yvanu McGill University Health Center4 aut
7001 a Gordon, Caroline4 aut
7001 a Bae, Sang Cheolu Hanyang University Hospital for Rheumatic Disease4 aut
7001 a Romero-Diaz, Juanitau Salvador Zubirán National Institute of Health Sciences and Nutrition4 aut
7001 a Sanchez-Guerrero, Jorgeu Mount Sinai Hospital of University of Toronto4 aut
7001 a Bernatsky, Sashau McGill University Health Center4 aut
7001 a Wallace, Daniel J.u Cedars-Sinai Medical Center4 aut
7001 a Isenberg, David A.u University College London4 aut
7001 a Rahman, Anisuru University College London4 aut
7001 a Merrill, Joan T.u Oklahoma Medical Research Foundation4 aut
7001 a Fortin, Paul R.u Laval University4 aut
7001 a Gladman, Dafna D.u University of Toronto4 aut
7001 a Bruce, Ian N.u Manchester University NHS Foundation Trust,University of Manchester4 aut
7001 a Petri, Michelle A.u Johns Hopkins University School of Medicine4 aut
7001 a Ginzler, Ellen M.4 aut
7001 a Dooley, Mary Anneu University of North Carolina4 aut
7001 a Ramsey-Goldman, Rosalindu Northwestern University Feinberg School of Medicine4 aut
7001 a Manzi, Susanu Allegheny Health Network4 aut
7001 a Jönsen, Andreasu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund SLE Research Group,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)reum-ajo
7001 a Van Vollenhoven, Ronald F.u University of Amsterdam4 aut
7001 a Aranow, Cynthiau Feinstein Institute for Medical Research4 aut
7001 a Mackay, Megganu Feinstein Institute for Medical Research4 aut
7001 a Ruiz-Irastorza, Guillermou Hospital de Cruces4 aut
7001 a Lim, S. Samu Emory University4 aut
7001 a Inanc, Murat4 aut
7001 a Kalunian, Kenneth C.u University of California, San Diego4 aut
7001 a Jacobsen, Sørenu Copenhagen University Hospital4 aut
7001 a Peschken, Christine A.u University of Manitoba4 aut
7001 a Kamen, Diane L.u Medical University of South Carolina4 aut
7001 a Askanase, Ancau Columbia University4 aut
7001 a Pons-Estel, Bernardo A.u Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR)4 aut
7001 a Cardwell, Francesca S.u University of Waterloo4 aut
7001 a Alarcón, Graciela S.4 aut
7001 a Clarke, Ann E.u Cumming School of Medicine4 aut
7102 a Cumming School of Medicineb Hospital Nacional Guillermo Almenara Irigoyen, EsSalud4 org
7730 t Annals of the Rheumatic Diseasesx 0003-4967
8564 u http://dx.doi.org/10.1136/ard-2024-225613y FULLTEXT
8564 8u https://lup.lub.lu.se/record/d903e1cb-1655-4f7b-a6c8-91fd6c2ad656
8564 8u https://doi.org/10.1136/ard-2024-225613

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy